VEGA-3 topline readout propels Opus Genetics toward presbyopia market

Rhea-AI Filing Summary

Opus Genetics (Nasdaq:OCUP) filed a Form 8-K disclosing topline results from VEGA-3, its second pivotal Phase 3 trial of Phentolamine Ophthalmic Solution 0.75 % for presbyopia. Numerical efficacy and safety data were not included, but management deemed the readout material and will host a webcast on June 26, 2025 at 8:00 a.m. ET to discuss the findings and give a corporate update.

The filing reiterates prior guidance that cash on hand should fund operations into 2H FY 2026, suggesting no immediate financing need. Exhibit 99.1 contains the full press release; no new contracts, financings, or governance changes were reported. Forward-looking-statement disclaimers reference previously disclosed risk factors.

Positive

• Announcement of topline results from the second pivotal Phase 3 VEGA-3 study for Phentolamine Ophthalmic Solution 0.75 %
• Management reaffirms cash runway sufficient to fund operations into 2H FY 2026, lowering near-term financing risk

Negative

• No quantitative efficacy or safety data disclosed, leaving investors unable to gauge trial success

Insights

Pharma Analyst

TL;DR – Phase 3 data announced; success unknown until numbers debut, but pivotal milestone reduces clinical timeline risk.

The company’s confirmation of VEGA-3 topline completion signals a key step toward an NDA filing. Although outcome metrics were withheld, completing a second pivotal trial typically satisfies FDA efficacy dataset requirements, narrowing regulatory risk. Investors must await full data to judge competitive positioning against approved drops, yet the milestone de-risks development timelines and could trigger partnership interest. With cash runway into 2H 2026, management has a buffer to analyze results and prepare regulatory submissions without near-term dilution pressure.

Risk Analyst

TL;DR – Cash runway eases financing risk; lack of efficacy figures keeps outcome uncertainty elevated.

Extending liquidity through 2H 2026 removes immediate covenant and dilution threats, a plus for shareholders. However, withholding quantitative endpoints makes it impossible to assess the probability of approval or market uptake, preserving binary risk around the asset that still drives the equity story. Until the full dataset and safety profile are revealed, valuation remains speculative. Investors should watch the webcast for clarity on primary-endpoint achievement and durability of effect.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 06/26/2025 - 07:06 AM Learn about SEC filing dates

FAQ

When did OCUP announce topline results from its VEGA-3 Phase 3 trial?

OCUP reported VEGA-3 topline results on June 26, 2025 via a Form 8-K filing.

What drug is being tested in OCUP's VEGA-3 study?

The trial evaluates Phentolamine Ophthalmic Solution 0.75 % for presbyopia.

How long will OCUP's current cash last?

Management expects cash on hand to fund operations into the second half of fiscal 2026.

Is OCUP hosting a call to discuss the VEGA-3 results?

Yes. A webcast and conference call is scheduled for June 26, 2025 at 8:00 a.m. ET.

Where can investors access the VEGA-3 webcast replay?

The live and archived webcast will be available in the Investors section of OCUP’s website.

Which exhibit contains the full press release on VEGA-3?

The detailed press release is filed as Exhibit 99.1 to the Form 8-K.

false000122862700012286272025-06-262025-06-26

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 26, 2025

Opus Genetics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-34079	11-3516358
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

8 Davis Drive Durham, NC		27713
(Address of principal executive offices)		(Zip Code)

(248) 957-9024

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	IRD	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

VEGA-3 Phase 3 Trial Topline Results

On June 26, 2025, Opus Genetics, Inc. (the “Company”) announced topline results from VEGA-3, its second pivotal Phase 3 trial evaluating Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein. As announced in the press release, the Company is hosting a webcast and conference call this morning at 8:00 a.m. Eastern Time to discuss recent clinical results and provide a corporate update. The live and archived webcast may be accessed on the Company’s website under the Investors section.

Cash Runway

As previously disclosed by the Company on June 23, 2025, the Company expects that its cash on hand will be sufficient to fund operations into the second half of fiscal year 2026.

Forward Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties posed by many factors and events that could cause the Company’s actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading “Risk Factors” included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, and in the Company’s other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The Company undertakes no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release, dated June 26, 2025.
104.1	Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	OPUS GENETICS, INC.
Date: June 26, 2025	By:	/s/ Dr. George Magrath
	Name:	Dr. George Magrath
	Title:	Chief Executive Officer